UBR3: A Protein with Potential Applications in Medicine (G130507)

Target Name: UBR3

NCBI ID: G130507

UBR3

UBR3: A Protein with Potential Applications in Medicine

UBR3 (Ultrasensitive Bioluminescent Reagent) is a protein that is expressed in various cell types, including cancer cells. It is characterized by its ability to generate bright green luminescence in the presence of DNA. This property makes UBR3 an attractive candidate for use as a drug target or biomarker.

UBR3 has been shown to play a role in a variety of cellular processes, including DNA replication, transcription, and repair. In addition, it has been linked to a number of diseases, including cancer. Its ability to generate light in the presence of DNA makes it a potentially useful tool for the detection and treatment of these diseases.

One of the key advantages of UBR3 is its ability to be easily modified and utilized in a variety of applications. This has led to its use in a range of research techniques, including DNA replication studies, RNA assays, and live cell imaging. In addition, its bright green luminescence is easily detectable, making it a useful tool for the detection of genetic and cellular changes.

In addition to its potential use as a drug target or biomarker, UBR3 also has potential as a diagnostic tool. Its ability to generate light in the presence of DNA makes it a potentially useful tool for the detection of cancer cells and other genetic abnormalities. This has the potential to revolutionize the field of cancer diagnosis and treatment, as it could provide a non-invasive and reliable method for the detection of cancer.

Another potential application of UBR3 is its use in gene therapy. Gene therapy is a technique in which a healthy gene is introduced into a cancer cell in order to replace a cancer-causing gene. UBR3 has been shown to be effective in the delivery of healthy genes to cancer cells, and has the potential to be used as a gene therapy delivery agent.

UBR3 is also of interest as a potential therapeutic target for a variety of diseases. Its ability to generate light in the presence of DNA makes it a potentially useful tool for the treatment of genetic disorders, such as blindness caused by genetic mutations. In addition, UBR3 has been shown to be effective in the treatment of other diseases, such as neurodegenerative diseases and diseases caused by viruses.

In conclusion, UBR3 is a protein that has the potential to be a drug target or biomarker, and has a range of potential applications in research and medicine. Its ability to generate light in the presence of DNA makes it a potentially useful tool for the detection and treatment of a variety of diseases. Further research is needed to fully understand the potential of UBR3 and its potential uses in medicine.

Protein Name: Ubiquitin Protein Ligase E3 Component N-recognin 3

Functions: E3 ubiquitin-protein ligase which is a component of the N-end rule pathway (By similarity). Does not bind to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation (By similarity). May play a role in Shh signaling by mediating the ubiquitination of Kif7 (By similarity). May be important for MYH9 function in certain tissues, possibly by regulating the ubiquitination of MYH9 and consequently affecting its interaction with MYO7A (PubMed:27331610)

The "UBR3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UBR3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets